BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) continues to cause significant morbidity and mortality. Overexpression of specific phase II gene products may represent an important biomarker. One regulator of phase II gene expression is the transcription factor nuclear factor E2 p45-related factor 2 (Nrf2). Nrf2 expression was evaluated in HNSCC, to determine whether it might serve as a biomarker for early detection of disease. METHODS: A tissue microarray was constructed of 141 HNSCC biopsy cores from 47 HNSCCs. In addition, histologically normal squamous mucosa was obtained from 7 patients. Protein expression was evaluated by immunohistochemistry. RESULTS: Nrf2 expression was increased in 91.5% of tumors. Expression of thioredoxin, a Nrf2-reguated gene product, was elevated in 75% of tumors. Keap1, which regulates the rate of Nrf2 ubiquitination and degradation, was relatively overexpressed in HNSCC compared with normal mucosa. CONCLUSIONS: Nrf2 expression may be a possible HNSCC candidate biomarker. (c) 2006 Wiley Periodicals, Inc.
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) continues to cause significant morbidity and mortality. Overexpression of specific phase II gene products may represent an important biomarker. One regulator of phase II gene expression is the transcription factor nuclear factor E2 p45-related factor 2 (Nrf2). Nrf2 expression was evaluated in HNSCC, to determine whether it might serve as a biomarker for early detection of disease. METHODS: A tissue microarray was constructed of 141 HNSCC biopsy cores from 47 HNSCCs. In addition, histologically normal squamous mucosa was obtained from 7 patients. Protein expression was evaluated by immunohistochemistry. RESULTS:Nrf2 expression was increased in 91.5% of tumors. Expression of thioredoxin, a Nrf2-reguated gene product, was elevated in 75% of tumors. Keap1, which regulates the rate of Nrf2 ubiquitination and degradation, was relatively overexpressed in HNSCC compared with normal mucosa. CONCLUSIONS:Nrf2 expression may be a possible HNSCC candidate biomarker. (c) 2006 Wiley Periodicals, Inc.
Authors: Luisa M Solis; Carmen Behrens; Wenli Dong; Milind Suraokar; Natalie C Ozburn; Cesar A Moran; Alejandro H Corvalan; Shyam Biswal; Stephen G Swisher; B Nebiyou Bekele; John D Minna; David J Stewart; Ignacio I Wistuba Journal: Clin Cancer Res Date: 2010-06-09 Impact factor: 12.531
Authors: Monique G P van der Wijst; Christian Huisman; Archibold Mposhi; Gerard Roelfes; Marianne G Rots Journal: Mol Oncol Date: 2015-03-19 Impact factor: 6.603
Authors: Shasha Tao; Shue Wang; Seyed Javad Moghaddam; Aikseng Ooi; Eli Chapman; Pak K Wong; Donna D Zhang Journal: Cancer Res Date: 2014-10-22 Impact factor: 12.701
Authors: G Rachakonda; K R Sekhar; D Jowhar; P C Samson; J P Wikswo; R D Beauchamp; P K Datta; M L Freeman Journal: Oncogene Date: 2010-05-03 Impact factor: 9.867